{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:16:51Z","timestamp":1790083011937,"version":"4.0.1"},"reference-count":24,"publisher":"Society of Nuclear Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,12,5]]},"published-print":{"date-parts":[[2025,3]]},"DOI":"10.2967\/jnumed.124.268340","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T13:45:24Z","timestamp":1738849524000},"page":"373-376","source":"Crossref","is-referenced-by-count":12,"title":["Exploring the Flare Phenomenon in Patients with Castration-Resistant Prostate Cancer: Enzalutamide-Induced PSMA Upregulation Observed on PSMA PET"],"prefix":"10.2967","volume":"66","author":[{"given":"Suzanne","family":"van der Gaag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke H.","family":"Bartelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephina C.C.","family":"Koppes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Hodolic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Hendrikse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"2025030410451222000_66.3.373.1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/pros.23868","article-title":"Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of 177Lu-PSMA-617 in LNCaP cells","volume":"79","author":"Kranzbuhler","year":"2019","journal-title":"Prostate."},{"key":"2025030410451222000_66.3.373.2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/pros.23522","article-title":"Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells","volume":"78","author":"Kranzbuhler","year":"2018","journal-title":"Prostate."},{"key":"2025030410451222000_66.3.373.3","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00432-021-03583-w","article-title":"Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga-PSMA uptake in LNCaP cells","volume":"147","author":"Mathy","year":"2021","journal-title":"J Cancer Res Clin Oncol."},{"key":"2025030410451222000_66.3.373.4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13550-015-0145-8","article-title":"Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy","volume":"5","author":"Meller","year":"2015","journal-title":"EJNMMI Res."},{"key":"2025030410451222000_66.3.373.5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pros.22910","article-title":"Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer","volume":"75","author":"Murga","year":"2015","journal-title":"Prostate."},{"key":"2025030410451222000_66.3.373.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2008.07.005"},{"key":"2025030410451222000_66.3.373.7","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.3390\/ijms22147431","article-title":"Enzalutamide enhances PSMA expression of PSMA-low prostate cancer","volume":"22","author":"Staniszewska","year":"2021","journal-title":"Int J Mol Sci."},{"key":"2025030410451222000_66.3.373.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.181800"},{"key":"2025030410451222000_66.3.373.9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13550-018-0451-z","article-title":"Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer","volume":"8","author":"Luckerath","year":"2018","journal-title":"EJNMMI Res."},{"key":"2025030410451222000_66.3.373.10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00259-019-04674-0","article-title":"New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide","volume":"47","author":"Rosar","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025030410451222000_66.3.373.11","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3390\/cancers14071696","article-title":"Upregulation of PSMA expression by enzalutamide in patients with advanced mCRPC","volume":"14","author":"Rosar","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2025030410451222000_66.3.373.12","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025030410451222000_66.3.373.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.222505"},{"key":"2025030410451222000_66.3.373.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227520"},{"key":"2025030410451222000_66.3.373.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.261972"},{"key":"2025030410451222000_66.3.373.16","doi-asserted-by":"crossref","unstructured":"Popescu L Matej S Lewitt R . Iterative image reconstruction using geometrically ordered subsets with list-mode data. In: Nuclear Science Symposium Conference Record. IEEE; 2004:3536\u20133540.","DOI":"10.1109\/NSSMIC.2004.1466649"},{"key":"2025030410451222000_66.3.373.17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40658-022-00504-9","article-title":"Shortened duration whole body 18F-FDG PET Patlak imaging on the Biograph Vision Quadra PET\/CT using a population-averaged input function","volume":"9","author":"van Sluis","year":"2022","journal-title":"EJNMMI Phys"},{"key":"2025030410451222000_66.3.373.18","first-page":"412","article-title":"New developments of EANM oncology PET\/CT guidelines and update of the EARL accreditation standards presentation","volume":"45","author":"Boellaard","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025030410451222000_66.3.373.19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13550-023-01048-4","article-title":"Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study","volume":"13","author":"Sonni","year":"2023","journal-title":"EJNMMI Res."},{"key":"2025030410451222000_66.3.373.20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025030410451222000_66.3.373.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223099"},{"key":"2025030410451222000_66.3.373.22","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.10.4923"},{"key":"2025030410451222000_66.3.373.23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/RLU.0000000000004529","article-title":"Increased PSMA expression in 177Lu-PSMA-617 scan in metastatic castrate-resistant prostate cancer patient treated with PSMA radioligand therapy and enzalutamide: a potential game-changer","volume":"48","author":"Aggarwal","year":"2023","journal-title":"Clin Nucl Med."},{"key":"2025030410451222000_66.3.373.24","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T13:45:41Z","timestamp":1741095941000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,3]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.2967\/jnumed.124.268340"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268340","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}